Pune, India, May 2023/MRFR Press Release/- Market Research Future has published a half-cooked research report on the global paraneoplastic syndrome market.

Paraneoplastic Syndrome Market Highlights

The paraneoplastic syndrome market is expected to grow at a CAGR of 5.80 % during the forecast period 2023 to 2030 and is projected to reach USD 460 Million by 2030.

A paraneoplastic syndrome is a set of signs and symptoms which develops from tumor or cancer. This syndrome can be mostly seen in middle-aged to older patients and are often seen in patients suffering from breast cancer, lung cancer, and lymphatic or ovarian cancer. Sometimes, patients with paraneoplastic syndrome do not show symptoms even after the diagnosis, but there exists a rare condition where patients show symptoms of the paraneoplastic syndrome even before diagnostic tests are carried out.

Factors such as the increasing prevalence of cancer, awareness regarding breast cancer, and an unhealthy lifestyle drive the growth of the global paraneoplastic syndrome market. Moreover, rising investments in research and development activities and increasing healthcare expenditure are few more factors driving the global paraneoplastic syndrome market.

On the other hand lack of awareness regarding cancer and stringent regulations may hamper the growth of the market.

The global paraneoplastic syndrome market is dominated by many market players. The key players in the market are engaged in new launches and strategic collaborations to hold their market position.  

Regional Analysis

The Americas is anticipated to dominate the global paraneoplastic syndrome market. The market growth in this region is attributed to the increasing geriatric population with paraneoplastic syndrome disorder, investment in research and development, and technological advancements.   

Europe is expected to be the second largest market in the globe owing to the increasing number of geriatric population, increasing awareness regarding breast cancer, the presence of disposable income, and increasing consumption of tobacco in this region.  

Asia-Pacific is anticipated to be the fastest growing market owing to the growing prevalence of paraneoplastic syndrome and cancer-related problems in developing countries, increasing disposable income, and growing healthcare expenditure.

The Middle East and Africa is expected to account for the lowest market share in the global paraneoplastic syndrome market due to low development, lack of technical knowledge, and poor medical facilities in developing economies in this region.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Paraneoplastic Syndrome Market Research Report

Segmentation

The global paraneoplastic syndrome market has been segmented into types, diagnosis, treatment, and end users. Based on types, the market is segmented into the cutaneous paraneoplastic syndrome, gastro-intestinal paraneoplastic syndrome, endocrine paraneoplastic syndrome, hematologic paraneoplastic syndrome, renal paraneoplastic syndrome, rheumatologic paraneoplastic syndromes, and neurologic paraneoplastic syndrome.

The market, by treatment, has been segmented into medication and therapies. Medication is further sub-segmented into corticosteroids, immunosuppressants, anti-seizure medications, plasmapheresis, and intravenous immunoglobulin (IVIg). On the basis of therapies, the market is further sub-segmented into physical therapy and speech therapy.

The market on the basis of diagnosis has been segmented into blood test, spinal tap (lumbar puncture), and imaging tests. Imaging tests are further sub-segmented into computerized tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and PET plus CT.

Based on end-user, the market is segmented into hospitals and clinics, diagnostic centers, and ambulatory care centers.

Key Players

Some of the key players in the global paraneoplastic syndrome market are Healthineers, Koninklijke Philips N.V., General Electric Company, Esaote SpA, NeuroLogica Corporation, Masimo Corporation, York Instruments Ltd., Neusoft Medical Systems, and Canon Medical Systems Corporation.